HealthPrize Technologies, LLC and MeadWestvaco are collaborating to integrate their proven adherence solutions to provide an end-to-end program to pharmaceutical companies, pharmacy chains, and the patients they serve. As part of the partnership, MWV’s calendared medication packaging will feature a link to HealthPrize’s Software-as-a-Service (SaaS) medication adherence and patient engagement platform.
Not only will this linkage connect patients to HealthPrize’s digital patient engagement programs, but HealthPrize will also offer providers real-time verification of their patients’ medication refills via scanning of the packaging. This data will empower providers to target patients in need of additional adherence counseling or other forms of assistance.
Medication non-adherence is a leading cause of poor clinical outcomes and increased healthcare costs. Industry analysts estimate poor medication adherence costs the U.S. healthcare system more than $290 billion in otherwise avoidable medical spending. The pharmaceutical industry’s global revenue loss due to non-adherence to medication for chronic conditions is estimated to be $564 billion, according to a recent study performed by Capgemini in collaboration with HealthPrize,
The HealthPrize platform leverages a combination of gamification, behavioral economic concepts, education and rewards to maximize motivational impact. In partnership with MWV, the HealthPrize programming now also can include education about the usage of adherence packaging and its benefits.
Patients enrolled in HealthPrize programs demonstrate persistently high engagement rates and materially higher prescription fill rates as measured by mean number of fills per patient, nearly 50 percent higher than supporting brands’ baselines, on average. The combined adherence benefits of the MWV calendared medication packaging and the HealthPrize platform should be unprecedented levels of patient engagement and lifts in adherence, even higher than those achieved by each platform alone.
MWV Healthcare’s solutions are proven and scalable, both when used alone and also as a foundation for broader adherence programs. A first-of-its-kind peer-reviewed study published in Clinical Therapeutics found that when used alone, MWV’s adherence packaging demonstrated a statistically significant impact over vials, improving adherence and persistence for long-term daily medications.
It has been shown to achieve an 80% proportion of days covered with up to 37% more patients versus standard vials, and a 41% increase in length of therapy when combined with other adherence programs. We also know from this peer-reviewed research that when interventions are integrated together to make more comprehensive adherence programs, adherence rates improve at materially greater levels.
